Antiangiogenic therapies in portal hypertension: A breakthrough in hepatology

Gastroenterologie Clinique et Biologique

Volumn 34, Issue 8-9, 2010, Pages 446-449

  Rosmorduc, O ^a  

^a HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PLATELET DERIVED GROWTH FACTOR; SORAFENIB; SUNITINIB; VASCULOTROPIN;

ANGIOGENESIS; ANTIANGIOGENIC THERAPY; HUMAN; INFLAMMATORY INFILTRATE; LIVER CANCER; LIVER CIRRHOSIS; LIVER FIBROSIS; NONHUMAN; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; SHORT SURVEY; SPLANCHNIC BLOOD FLOW;

ANGIOGENESIS INHIBITORS; ANOXIA; HUMANS; HYPERTENSION, PORTAL; LIVER CIRRHOSIS; NEOVASCULARIZATION, PATHOLOGIC; SPLANCHNIC CIRCULATION;

EID: 77957021043     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gcb.2010.05.007     Document Type: Short Survey

References (25)

1. Rosmorduc O., Wendum D., Corpechot C., Galy B., Sebbagh N., Raleigh J., et al. Hepatocellular hypoxia-induced vascular endothelial growth factor expression and angiogenesis in experimental biliary cirrhosis. Am J Pathol 1999, 155:1065-1073.
2. Corpechot C., Barbu V., Wendum D., Kinnman N., Rey C., Poupon R., et al. Hypoxia-induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis. Hepatology 2002, 35:1010-1021.
3. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003, 9:653-660.
4. Shah V. Molecular mechanisms of increased intrahepatic resistance in portal hypertension. J Clin Gastroenterol 2007, 41(Suppl. 3):S259-S261.
5. Rappaport A.M., MacPhee P.J., Fisher M.M., Phillips M.J. The scarring of the liver acini (cirrhosis). Tridimensional and microcirculatory considerations. Virchows Arch A Pathol Anat Histopathol 1983, 402:107-137.
6. Huet P.M., Goresky C.A., Villeneuve J.P., Marleau D., Lough J.O. Assessment of liver microcirculation in human cirrhosis. J Clin Invest 1982, 70:1234-1244.
7. Housset C., Rockey D.C., Bissell D.M. Endothelin receptors in rat liver: lipocytes as a contractile target for endothelin 1. Proc Natl Acad Sci U S A 1993, 90:9266-9270.
8. Rockey D.C., Housset C.N., Friedman S.L. Activation-dependent contractility of rat hepatic lipocytes in culture and in vivo. J Clin Invest 1993, 92:1795-1804.
9. Rockey D.C., Fouassier L., Chung J.J., Carayon A., Vallee P., Rey C., et al. Cellular localization of endothelin-1 and increased production in liver injury in the rat: potential for autocrine and paracrine effects on stellate cells. Hepatology 1998, 27:472-480.
10. Yamamoto T., Kobayashi T., Phillips M.J. Perinodular arteriolar plexus in liver cirrhosis. Scanning electron microscopy of microvascular casts. Liver 1984, 4:50-54.
11. Haratake J., Hisaoka M., Yamamoto O., Horie A. Morphological changes of hepatic microcirculation in experimental rat cirrhosis: a scanning electron microscopic study. Hepatology 1991, 13:952-956.
12. Fernandez M., Meijas M., Angermayr B., Garcia-Pagan J.C., Rodés J., Bosch J. Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats. J Hepatol 2005, 43:98-103.
13. Fernandez M., Vizutti F., Garcia-Pagan J.C., Rodés J., Bosch J. Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice. Gastroenterology 2004, 126:886-894.
14. Tugues S., Fernandez-Varo G., Munoz-Luque J., Ros J., Arroyo V., Rodés J., et al. Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology 2007, 46:1919-1926.
15. Lindahl P., Johansson B.R., Leveen P., Betsholtz C. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 1997, 277:242-245.
16. Reiberger T., Angermayr B., Schwabl P., Rohr-Udilova N., Mitterhauser M., Gangl A., et al. Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats. J Hepatol 2009, 51:865-873.
17. Meijas M., Garcia-Pagan J.C., Tiani C., Miquel R., Bosch J., Fernandez M. Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. Hepatology 2009, 49:1245-1256.
18. Kidoya H., Ueno M., Yamada Y., Mochizuki N., Nakata M., Yano T., et al. Spatial and temporal role of the apelin/APJ system in the caliber size regulation of blood vessels during angiogenesis. EMBO J 2008, 27:522-534.
19. Masri B., Knibiehler B., Audigier Y. Apelin signalling: a promising pathway from cloning to pharmacology. Cell Signal 2005, 17:415-426.
20. Principe A., Melgar-Lesmes P., Fernandez-Varo G., del Arbol L.R., Ros J., Morales-Ruiz M., et al. The hepatic apelin system: a new therapeutic target for liver disease. Hepatology 2008, 48:1193-1201.
21. Tiani C., Garcia-Pras E., Mejias M., de Gottardi A., Berzigotti A., Bosch J., et al. Apelin signaling modulates splanchnic angiogenesis and portosystemic collateral vessel formation in rats with portal hypertension. J Hepatol 2009, 50:296-305.
22. Mejias M., Garcia-Pras E., Tiani C., Bosch J., Fernandez M. The somatostatin analogue octreotide inhibits angiogenesis in the earliest, but not in advanced, stages of portal hypertension in rats. J Cell Mol Med 2008, 12:1690-1699.
23. Patsenker E., Popov Y., Stickel F., Schneider V., Ledermann M., Sagesser H., et al. Pharmacological inhibition of integrin alphavbeta3 aggravates experimental liver fibrosis and suppresses hepatic angiogenesis. Hepatology 2009, 50:1501-1511.
24. Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:378-390.
25. Siegel A., Cohen E., Lehrer D., Goldenberg A., Knox J., Chen H., et al. Phase II trial evaluating the clinical and biological effects of bevacizumab in unresecable hepatocellular carcinoma. J Clin Oncol 2008, 26:2992-2998.